Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura

This publication has 27 references indexed in Scilit:

• Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
  Journal of Thrombosis and Haemostasis, 2019
• Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura
  New England Journal of Medicine, 2019
• Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
  New England Journal of Medicine, 2019
• Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis
  Clinical and Applied Thrombosis/Hemostasis, 2019
• Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura
  Blood, 2017
• Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
  Journal of Thrombosis and Haemostasis, 2017
• Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study
  The Lancet Haematology, 2017
• Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
  New England Journal of Medicine, 2016
• Derivation and Prospective Validation of a Predictive Score for the Rapid Diagnosis of Thrombotic Thrombocytopenic Purpura: The Plasmic Score
  Blood, 2014
• Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura
  Blood, 2013